Keyword:Tertomotide,922174-60-5,Tertomotide Immunotherapeutic Peptide

Cross-Border Exploration: From Anticancer Vaccine to Multi-Active Candidate Molecule

In the field of peptide drug development, there exists a molecule — Tertomotide (CAS No.: 922174-60-5). Initially developed as an anticancer vaccine, it has unlocked unexpected biological potential in subsequent studies, emerging as a versatile candidate worthy of attention in scientific research. Its related research has also provided new insights into the cross-border applications of peptide drugs.

Basic Properties and Initial R&D Positioning of Tertomotide

Tertomotide is essentially a peptide vaccine composed of 16 amino acids, derived from the human telomerase reverse transcriptase (hTERT) sequence. It was originally designed for the treatment of various cancers including pancreatic cancer, melanoma, and non-small cell lung cancer. Its core mechanism of action lies in its ability to bind to multiple major histocompatibility complex (MHC) class I and class II molecules, activate CD4+ and CD8+ T cells, and exert anti-tumor immune effects through its own immunogenicity. This characteristic laid the foundation for its early anticancer research.

Unexpectedly Unlocked Anti-Inflammatory Activity: A Beneficial "Off-Target Effect"

What truly distinguishes this molecule is its unexpectedly discovered anti-inflammatory activity — a beneficial "off-target effect". A South Korean scientific study demonstrated that in monocyte cell lines stimulated by lipopolysaccharide (LPS) or phorbol 12-myristate 13-acetate (PMA), Tertomotide significantly reduces the levels of pro-inflammatory cytokines such as tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), and interleukin-8 (IL-8). Meanwhile, it inhibits the NF-κB signaling pathway and the activation of ERK1/2 and P38 MAPK induced by TNF-α. This study suggests that Tertomotide is expected to become a potential anti-inflammatory drug, and also serves as a typical fusion research case of "computationally designed immunological peptides exerting unexpected biological activities".

Expanding Research Boundaries: Potential Value in Neuroprotection

Furthermore, the research scope of Tertomotide continues to expand. Studies have indicated that its hydrochloride form (Tertomotide hydrochloride) also possesses neuroprotective effects, showing potential value in research related to Alzheimer’s disease, thus offering a new direction for the exploration of treatments for neurodegenerative diseases.

Research Summary and Future Prospects

From an anticancer vaccine to an anti-inflammatory candidate molecule, and further to potential exploration in the field of neuroprotection, the research journey of Tertomotide (922174-60-5) highlights the structural flexibility and functional diversity of peptide molecules. Currently, research on its clinical translation is still progressing. With the deepening of research, it is believed that this peptide molecule with multiple potentials such as immunomodulation and anti-inflammation will bring new possibilities for the treatment of more diseases, and also provide valuable references for the cross-border research and development of peptide drugs.